Comparing Autonomix Medical (NASDAQ:AMIX) and AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ:ATRC) and Autonomix Medical (NASDAQ:AMIX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Earnings & Valuation

This table compares AtriCure and Autonomix Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$399.24 million	4.96	-$30.44 million	($0.83)	-48.89
Autonomix Medical	N/A	N/A	-$15.43 million	($16.07)	-0.19

Autonomix Medical has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are owned by institutional investors. 3.2% of AtriCure shares are owned by insiders. Comparatively, 32.4% of Autonomix Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares AtriCure and Autonomix Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AtriCure	-8.70%	-8.12%	-6.21%
Autonomix Medical	N/A	-542.11%	-236.92%

Analyst Ratings

This is a breakdown of recent ratings and target prices for AtriCure and Autonomix Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0	0	8	0	3.00
Autonomix Medical	0	0	1	0	3.00

AtriCure currently has a consensus price target of $43.38, suggesting a potential upside of 6.89%. Autonomix Medical has a consensus price target of $28.00, suggesting a potential upside of 806.15%. Given Autonomix Medical’s higher probable upside, analysts plainly believe Autonomix Medical is more favorable than AtriCure.

Summary

AtriCure beats Autonomix Medical on 6 of the 11 factors compared between the two stocks.

About AtriCure

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.